Clinical trials: Blood Platelet Disease
Unilateral Primary Osteoarthritis of Knee, Osteoarthritis Knee
Microdrilling Surgery for Full Thickness Chondral Lesions of the Knee Augmented With Concentrated Bone Marrow Aspirate, Platelet Rich Plasma and Hyaluronic Acid
This study seeks to evaluate a treatment for multiple full thickness chondral lesions in the knee. Eligible subjects will undergo a microdrilling surgery and up to 12 post operative intra-articular injections of bone marrow…
- Conditions
- Unilateral Primary Osteoarthritis of Knee, Osteoarthritis Knee, Degeneration; Articular Cartilage, Knee, Degenerative Lesion of Articular Cartilage of Knee
- Trial name
- NCT02285725
- Testing
- Microdrilling Surgery, Injections of BMAC + PRP + HA
- Volunteers
- 21 people
- Sponsor
- Joseph E. Broyles
Atypical Hemolytic Uremic Syndrome
Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS
Atypical hemolytic syndrome (aHUS) is a severe renal disease affecting children and adults. It is characterized by the occlusion of intrarenal vessels due to the presence of platelet/fibrin thrombi, and leads to end-stage renal…
- Trial name
- STOPECU (NCT02574403)
- Testing
- eculizumab
- Where
- 22 sites in France
- Volunteers
- 58 people
- Sponsor
- Nantes University Hospital
Severe Aplastic Anemia
Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)
Background: Severe aplastic anemia (SAA) is a rare and serious blood disorder. It causes the immune system to turn against bone marrow cells.
- Trial name
- NCT04304820
- Testing
- Eltrombopag, Cyclosporine, Horse-Anti-thymocyte-Globulin
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Thrombocytopenia, Cytarabine Causing Adverse Effects in Therapeutic Use
Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With Lymphoma
This phase 2 trial studies the efficacy and safety of Avatrombopag for the primary prevention of thrombocytopenia induced by cytarabine-based chemotherapy in patients with lymphoma
- Conditions
- Thrombocytopenia, Cytarabine Causing Adverse Effects in Therapeutic Use, Lymphoma
- Trial name
- NCT04797182
- Testing
- avatrombopag
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Sun Yat-sen University
Myeloproliferative Neoplasms of, Polycythemia Vera
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
The purpose of this study is to determine a dose of LY2784544 that may be safely administered to participants with myeloproliferative neoplasms.
- Conditions
- Myeloproliferative Neoplasms of, Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis
- Trial name
- NCT01520220
- Testing
- LY2784544
- Where
- 9 sites in United States
- Volunteers
- 100 people
- Sponsor
- Eli Lilly and Company
Thrombotic Microangiopathies
Automated Surveillance, Alert, and Rapid Diagnosis of Thrombotic Microangiopathies: the ASARD-TMA Study
Recently a pilot study was conducted to evaluate the impact of an electronic alert (e-alert) triggered by the automated algorithm in the efficiency and rapidity in TMA patients' identification in our University Hospital A.
- Trial name
- ASARD-TMA (NCT05996679)
- Volunteers
- 29 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Knee Osteoarthritis
Treatment of Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells With Platelet Rich Plasma
Purpose: To determine the safety, feasibility and effectiveness (clinical and radiological) of intra-articular administration of autologous mesenchymal stem cells (MSCs) with platelet richa plasma (PRGF) in patients with knee…
- Trial name
- CMM-PRGF/ART (NCT02365142)
- Testing
- 100 million Bone marrow mesenchimal stem cells, Platelet Rich plasma (PRGF)
- Where
- 2 sites in Spain
- Volunteers
- 38 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Polycythemia Vera, Essential Thrombocytosis
Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders
The three main chronic myeloproliferative disorders are polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF).
- Conditions
- Polycythemia Vera, Essential Thrombocytosis, Idiopathic Myelofibrosis, Neutrophils
- Trial name
- NCT00433862
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Coronary Artery Disease
Tongxinluo Improve High on Clopidogrel Platelet Reactivity Patients With Coronary Heart Disease
Tongxinluo is a kind of Chinese patent drug,which could promote blood circulation.Recent reports suggested that tongxinluo's effectiveness in reducing the thrombin activity.In this prospective randomized study,all patients in…
- Trial name
- Talent (NCT01721590)
- Testing
- Tongxinluo
- Where
- 3 sites in China
- Volunteers
- 134 people
- Sponsor
- Han Yaling
Primary Thrombocytopenia
Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia
NewGam is a newly developed human normal immunoglobulin solution for intravenous administration (IGIV). This study will evaluate the safety and efficacy of NewGam 10% in patients with primary immune thrombocytopenia.
- Trial name
- NCT01349790
- Testing
- NewGam
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Octapharma
Thrombocytopenia
Collection of Peripheral Blood From Patients With Hematologic Malignancies With Thrombocytopenia
The purpose of the research project is to collect one blood sample from participants who are affected by very low platelets as a result of their condition or their treatment.
- Trial name
- NCT06824727
- Testing
- Baseline cell blood counts
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Case Comprehensive Cancer Center
Von Willebrand Diseases, Postpartum Hemorrhage
Prevent Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial
This is a single-center randomized phase III clinical trial, the VWD-Woman Trial, in which 20 pregnant subjects with von Willebrand disease (VWD), defined as VWF ristocetin co-factor activity (VWF:RCo) <0.50 IU/ml (historic) and…
- Trial name
- NCT04344860
- Testing
- Recombinant Von Willebrand factor, Tranexamic Acid Injection [Cyklokapron]
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Nicoletta C Machin
Late-Onset Neonatal Sepsis, Necrotising Enterocolitis
Markers of Platelet Activation foR Identification of Late Onset Sepsis in Preterm Infants
The PARENT study will examine platelet and endothelial associated proteins in preterm infants being investigated for late onset sepsis (LOS) to see if infants with fulminant sepsis can be prospectively identified using these…
- Conditions
- Late-Onset Neonatal Sepsis, Necrotising Enterocolitis, Culture Negative Neonatal Sepsis
- Trial name
- PARENT (NCT05530330)
- Testing
- Platelet/Endothelial proteomics
- Where
- 2 sites in Ireland
- Volunteers
- 268 people
- Sponsor
- University College Dublin
Coronary Artery Disease, Diabetes Mellitus, Type 2
Platelet Inhibition of Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients After Elective Percutaneous Coronary Intervention
This will be a single-center, randomized, open-label, active-controlled, parallel-group study to investigate the platelet inhibition of Ticagrelor versus Clopidogrel with acetylsalicylic acid (ASA) as background therapy in…
- Trial name
- PLATIDE-PCI (NCT02748330)
- Testing
- Ticagrelor, Clopidogrel, Aspirin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking Union Medical College Hospital
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia
Phase 3, randomized, controlled study to evaluate the safety and efficacy of oral pacritinib compared to Best Available Therapy (BAT) in patients with thrombocytopenia and primary or secondary myelofibrosis.
- Conditions
- Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- PAC326 (NCT02055781)
- Testing
- Pacritinib, Best Available Therapy
- Where
- 122 sites in United States, Australia and 10 more
- Volunteers
- 311 people
- Sponsor
- CTI BioPharma
Von Willebrand's Disease
Phase I Study of Human Von Willebrand Factor for Von Willebrand's Disease
OBJECTIVES: I. Evaluate the effect of a new von Willebrand factor concentrate on bleeding time, in vivo recovery, and circulating half-life of the infused factor in patients with von Willebrand's disease. II.
- Trial name
- NCT00004667
- Testing
- von Willebrand factor
- Volunteers
- 10 people
- Sponsor
- National Center for Research Resources (NCRR)
Colorectal Neoplasm, Colorectal Cancer
New Individualized Therapy Trial for Metastatic Colorectal Cancer
The purpose of this study is to evaluate the safety and tolerability of imatinib mesylate in combination with panitumumab for the treatment of stage IV colorectal cancer that has spread to the liver.
- Trial name
- NITMEC (NCT00867334)
- Testing
- Imatinib mesylate and panitumumab, Standard-of-care treatment with panitumumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Inova Health Care Services
Acute Coronary Syndrome
Evaluation of Ticagrelor Anti Platelet and Pleiotropic Effects in Patients Undergoing Percutaneous Coronary Intervention for an Acute Coronary Syndrome
Ticagrelor is a new P2Y12 ADP receptor antagonist. This drug demonstrated a faster onset of action and a higher potency compared to clopidogrel standard regimen.
- Trial name
- NCT01626534
- Testing
- Clopidogrel, trigagrelor
- Where
- France
- Volunteers
- 125 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe thrombocytopenia (platelet count <50,000/μL).
- Conditions
- Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- PACIFICA (NCT03165734)
- Testing
- Pacritinib, Physician's Choice medications
- Where
- 207 sites in United States, Australia and 22 more
- Volunteers
- 407 people
- Sponsor
- Swedish Orphan Biovitrum
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer
This phase II trial studies how well tacrolimus and mycophenolate mofetil works in preventing graft-versus-host disease in patients who have undergone total-body irradiation (TBI) with or without fludarabine phosphate followed by…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00089011
- Testing
- fludarabine phosphate, total-body irradiation, mycophenolate mofetil
- Where
- 5 sites in United States, Italy
- Volunteers
- 150 people
- Sponsor
- Fred Hutchinson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.